The Genomic and Biologic Landscapes of Breast Cancer and Racial Differences DOI Open Access

Sampath Rukshani Galappaththi,

Kelly R. Smith,

Enas S. Alsatari

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(23), P. 13165 - 13165

Published: Dec. 7, 2024

Breast cancer is a significant health challenge worldwide and the most frequently diagnosed among women globally. This review provides comprehensive overview of breast biology, genomics, microbial dysbiosis, focusing on its various subtypes racial differences. primarily classified into carcinomas sarcomas, with constituting cases. Epidemiology risk factors are important for public intervention. Staging grading, based TNM Nottingham grading systems, respectively, crucial to determining clinical outcome treatment decisions. Histopathological include in situ invasive carcinomas, such as ductal carcinoma (IDC) lobular (ILC). The explores molecular subtypes, including Luminal A, B, Basal-like (Triple Negative), HER2-enriched, delves cancer's histological progression patterns. Recent research findings related nuclear mitochondrial genetic alterations, epigenetic reprogramming, role microbiome dysbiosis differences also reported. an update current diagnostics modalities.

Language: Английский

Revolutionizing Cancer Detection: Harnessing Quantum Dots and Graphene-Based Nanobiosensors for Lung and Breast Cancer Diagnosis DOI
Soheil Sadr, Abbas Rahdar, Sadanand Pandey

et al.

BioNanoScience, Journal Year: 2024, Volume and Issue: 15(1)

Published: Dec. 13, 2024

Language: Английский

Citations

9
First versus second-generation molecular profiling tests: How both can guide decision-making in early-stage hormone-receptor positive breast cancers? DOI Creative Commons
Flora Nguyen Van Long, Brigitte Poirier,

Christine Desbiens

et al.

Cancer Treatment Reviews, Journal Year: 2025, Volume and Issue: 135, P. 102909 - 102909

Published: Feb. 27, 2025

Hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) tumors represent the most common types of early-stage breast cancer. However, their response to adjuvant systemic treatments varies widely due tumor heterogeneity. Current decisions for treatment rely heavily on clinical pathological characteristics, which can sometimes lead overtreatment. Accurately identifying patients who will benefit from chemotherapy at an individual level remains a challenge. Multigene profiling assays are now used in clinics better assess recurrence risk HR+ disease. In this report, we examine advantages limitations two molecular tests-Oncotype DX Prosigna. Both Oncotype Prosigna have been demonstrated be effective prognostic tools early cancer, with also being validated as predictive tool guide decisions. We focus studies that directly compare these tests discuss how strengths leveraged improve decision-making cancers. Finally, highlight remaining knowledge gaps propose directions future research.

Language: Английский

Citations

1
Non-coding RNAs, a double-edged sword in breast cancer prognosis DOI Creative Commons
Maryam Solaimani, Sahar Hosseinzadeh, Mozhgan Abasi

et al.

Cancer Cell International, Journal Year: 2025, Volume and Issue: 25(1)

Published: April 1, 2025

Cancer is a rising issue worldwide, and numerous studies have focused on understanding the underlying reasons for its occurrence finding proper ways to defeat it. By applying technological advances, researchers are continuously uncovering updating treatments in cancer therapy. Their vast functions regulation of cell growth proliferation their significant role progression diseases, including cancer. This review provides comprehensive analysis ncRNAs breast cancer, focusing long non-coding RNAs such as HOTAIR, MALAT1, NEAT1, well microRNAs miR-21, miR-221/222, miR-155. These pivotal regulating proliferation, metastasis, drug resistance, apoptosis. Additionally, we discuss experimental approaches that useful studying them highlight advantages challenges each method. We then explain results these clinical trials offer insights future by discussing major existing gaps. On basis an extensive number studies, this valuable into potential Key findings show even though undeniable there still complications associated with therapeutic use. Moreover, absence sufficient experiments regarding application mouse models, which area work on. emphasizing crucial ncRNAs, underscores need innovative further explore

Language: Английский

Citations

1
NFR2/ABC transporter axis in drug resistance of breast cancer cells DOI

Zinat Sargazi,

Yalda Yazdani,

Amir Tahavvori

et al.

Molecular Biology Reports, Journal Year: 2023, Volume and Issue: 50(6), P. 5407 - 5414

Published: April 20, 2023

Language: Английский

Citations

17
APOC1 is a prognostic biomarker associated with M2 macrophages in ovarian cancer DOI Creative Commons
Shimin Yang,

Jingxiao Du,

Wei Wang

et al.

BMC Cancer, Journal Year: 2024, Volume and Issue: 24(1)

Published: March 21, 2024

Abstract Background Recent studies have demonstrated that APOC1 is associated with cancer progression, exerting cancer-promoting and immune infiltration-promoting effects. Nevertheless, there currently no report on the presence of in ovarian (OV). Method In this study, we conducted data analysis using GEO TCGA databases. We a thorough bioinformatics to investigate function OV, utilizing various platforms including cBioPortal, STRING, GeneMANIA, LinkedOmics, GSCALite, TIMER, CellMarker. Additionally, performed immunohistochemical staining tissue microarrays vitro cellular assays validate our findings. Result Our findings reveal expression significantly upregulated OV compared normal tissues. Importantly, patients high levels show poorer prognosis. Furthermore, study exerted crucial promoting capacity cells proliferate, migrate, invade. identified genes co-expressed are primarily adaptive responses. Notably, exhibit correlation M2 Tumor-associated Macrophages (TAMs). Conclusion emerges as promising prognostic biomarker for exhibits significant association TAMs OV.

Language: Английский

Citations

8
Forward attention-based deep network for classification of breast histopathology image DOI
Sudipta Roy, Pankaj Jain,

Kalyan Tadepalli

et al.

Multimedia Tools and Applications, Journal Year: 2024, Volume and Issue: 83(40), P. 88039 - 88068

Published: March 22, 2024

Language: Английский

Citations

8
A Comprehensive Review on Electrochemical Nano Biosensors for Precise Detection of Blood-Based Oncomarkers in Breast Cancer DOI Creative Commons
Mahdi Sadeghi, Somayeh Sadeghi, Seyed Morteza Naghib

et al.

Biosensors, Journal Year: 2023, Volume and Issue: 13(4), P. 481 - 481

Published: April 16, 2023

Breast cancer (BC), one of the most common and life-threatening cancers, has highest incidence rate among women. Early diagnosis BC oncomarkers is considered effective strategy for detecting treating BC. Finding type stage in women as soon possible greatest ways to stop its negative effects on medical treatment. The development biosensors early, sensitive, selective detection recently attracted much attention. An electrochemical nano biosensor (EN) a very suitable option powerful tool diagnosis. This comprehensive review provides information about prevalence pathobiology BC, recent advances clinically available oncomarkers, point-of-care (POC) various using nanomaterial-based signal amplification techniques.

Language: Английский

Citations

16
Proteomics-Based Identification of Dysregulated Proteins and Biomarker Discovery in Invasive Ductal Carcinoma, the Most Common Breast Cancer Subtype DOI Creative Commons

Anca-Narcisa Neagu,

Danielle Whitham,

Logan Seymour

et al.

Proteomes, Journal Year: 2023, Volume and Issue: 11(2), P. 13 - 13

Published: April 3, 2023

Invasive ductal carcinoma (IDC) is the most common histological subtype of malignant breast cancer (BC), and accounts for 70–80% all invasive BCs. IDC demonstrates great heterogeneity in clinical histopathological characteristics, prognoses, treatment strategies, gene expressions, proteomic profiles. Significant determinants progression from intraductal pre-invasive lesions breast, which characterize a situ (DCIS), to IDC, are still poorly identified, validated, clinically applied. In era “6P” medicine, it remains challenge determine patients should be over-treated versus need actively monitored without aggressive treatment. The major difficulties designating DCIS may solved by understanding integrated genomic, transcriptomic, bases invasion. this review, we showed that multiple proteomics-based techniques, such as LC–MS/MS, MALDI-ToF MS, SELDI-ToF-MS, MALDI-ToF/ToF MALDI-MSI or MasSpec Pen, applied in-tissue, off-tissue, BC cell lines liquid biopsies, improve diagnosis well its prognosis monitoring. Classic proteomics strategies allow identification dysregulated protein biological processes, interrelated pathway analyses based on aberrant protein–protein interaction (PPI) networks have been improved perform non-invasive/minimally biomarker detection early-stage IDC. Thus, modern surgical oncology, highly sensitive, rapid, accurate MS-based has coupled with “proteome point sampling” methods profiling vivo characterization”, minimal tissue removal, ex differentiation delimitation For low-molecular-weight proteins fragments bodily fluids, LC–MS/MS MALDI-MS techniques enrich capture biomarkers were previously invisible techniques. Moreover, characterization isoforms, including posttranslational modifications (PTMs), also essential emphasize specific molecular mechanisms, assure breast.

Language: Английский

Citations

15
The Critical Impact of Sphingolipid Metabolism in Breast Cancer Progression and Drug Response DOI Open Access
Paola Antonia Corsetto, Stefania Zava, Angela Maria Rizzo

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(3), P. 2107 - 2107

Published: Jan. 20, 2023

Breast cancer is the second leading cause of cancer-related death in women world, and its management includes a combination surgery, radiation therapy, chemotherapy, immunotherapy, whose effectiveness depends largely, but not exclusively, on molecular subtype (Luminal A, Luminal B, HER2+ Triple Negative). All breast subtypes are accompanied by peculiar substantial changes sphingolipid metabolism. Alterations metabolite levels, such as ceramides, dihydroceramide, sphingosine, sphingosine-1-phosphate, sphingomyelin, well their biosynthetic catabolic enzymatic pathways, have emerged mechanisms which cells grow, respond to or escape therapeutic interventions could take diagnostic prognostic value. In this review, we summarize current landscape around two main themes: 1. metabolites, enzymes transport proteins that been found dysregulated human and/or tissues; 2. sphingolipid-driven allow evade therapies. Having complete picture impact metabolism development progression may provide an effective means improve personalize treatments reduce associated drug resistance.

Language: Английский

Citations

13
Lectins as a promising therapeutic agent for breast cancer: A review DOI Creative Commons

Keerti Singh,

Lokita Agrawal,

Rhea Gupta

et al.

Breast Disease, Journal Year: 2024, Volume and Issue: 43(1), P. 193 - 211

Published: June 20, 2024

Efficient treatment of cancer has been a subject research by scientists for many years. Current treatments cancer, such as radiotherapy, chemotherapy and surgery have used in traditional combination therapy, but they major setbacks like non-specificity, non-responsiveness certain types towards treatment, tumor recurrence, etc. Epidemiological data shown that breast accounts 14% cases occurring Indian women. In recent years, started to focus on the use natural compounds lectins obtained from various sources counter side effects therapy. Lectins Sambucus nigra Agglutinin, Maackia amurensis lectin, Okra lectins, Haliclona caerulea Sclerotium rolfsii etc., discovered both diagnostic therapeutic potential patients. found inhibitory cell activities neo-angiogenesis, causing cycle arrest at G1 phase, inducing apoptosis. The idea behind diagnostics therapeutics is their capability bind glycosylated proteins are expressed surface. This review focuses an exploration roles post-translational modification cells, especially glycosylation, diagnosis therapeutics.

Language: Английский

Citations

5